A Viagra follow-up? Drug used to treat glaucoma actually grows human hair

If you're balding and want your hair to grow back, then here is some good news. A new research report appearing online in The FASEB Journal shows how the FDA-approved glaucoma drug, bimatoprost, causes human hair to regrow. It's been commercially available as a way to lengthen eyelashes, but these data are the first to show that it can actually grow human hair from the scalp.

"We hope this study will lead to the development of a new therapy for balding which should improve the quality of life for many people with hair loss," said Valerie Randall, a researcher involved in the work from the University of Bradford, Bradford, UK. "Further research should increase our understanding of how hair follicles work and thereby allow new for many hair growth disorders."

To make this discovery, Randall and colleagues conducted three sets of experiments. Two involved human cells and the other involved mice. The tests on human cells involved using hair follicles growing in organ culture as well as those take directly from the human scalp. In both of these experiments, the scientists found that bimatoprost led to . The third set of experiments involved applying bimatoprost to the skin of bald spots on mice. As was the case with , the drug caused hair to regrow.

"This discovery could be the long-awaited follow up to Viagra that middle-aged men have been waiting for," said Gerald Weissmann, MD, editor-in-chief of The . "Given that the drug is already approved for human use and its safety profile is generally understood, this looks like a promising discovery that has been right in front of our eyes the whole time. On to the front of our scalp!"

More information: FASEB J doi:10.1096/fj.12-218156

Related Stories

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments